Results 321 to 330 of about 266,823 (339)

Anti-VEGF therapy in pituitary carcinoma

Pituitary, 2011
We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken.
Ortiz, Leon D., Kovacs, Kalman, Horvath, Eva, Rotondo, Fabio, Fadul, Camilo E., Uribe, Humberto, Ersen, Ayca, Scheithauer, Bernd W., Syro, Luis V.   +8 more
openaire   +3 more sources

Intravitreal Anti-VEGF Therapy for Retinal Macroaneurysm

Klinische Monatsblätter für Augenheilkunde, 2013
We evaluated the effect of intravitreal anti-vascular endothelial growth factor therapy using bevacizumab or ranibizumab for retinal macroaneurysms with macular exudation.In a retrospective interventional case series patients with retinal macroaneurysms were treated with either 1.25 mg intravitreal bevacizumab or 0.5 mg ranibizumab as first-line ...
Zweifel, S A, Tönz, M S, Pfenninger, L, Becker, M, Michels, S   +4 more
openaire   +2 more sources

New Anti-VEGF Drugs in Ophthalmology

Current Drug Targets, 2020
: This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. : Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
openaire   +2 more sources

ANTI VEGF - VIEWPOINTS

EyeQuest, 2021
Deepak Agrawal, Muna Bhende, Sourav Sinha, Manish Nagpal, Anand Rajendran   +4 more
openaire   +1 more source

Antiangiogenesis, Anti-VEGF(R) and Outlook

2007
Tumor angiogenesis and antiangiogenesis has moved from an exotic research topic into clinical practice defining a new and promising avenue of targeted cancer therapy. Starting with a historical perspective on tumor angiogenesis, this review provides the basic concepts and classification of angiogenesis inhibition.
openaire   +2 more sources

Endophthalmitis After Anti-VEGF Injections

Ophthalmology, 2009
Kathryn S, Klein, Mark K, Walsh, Tarek S, Hassan, Lawrence S, Halperin, Alessandro A, Castellarin, Daniel, Roth, Sarah, Driscoll, Jonathan L, Prenner   +7 more
openaire   +2 more sources

Stroke and Anti-VEGF Therapy

Ophthalmology, 2011
Takashi, Ueta, Harushi, Mori, Akira, Kunimatsu, Takuhiro, Yamaguchi, Yasuhiro, Tamaki, Yasuo, Yanagi   +5 more
openaire   +2 more sources

Biosimilar anti-VEGF—Yardsticks to ensure biosimilarity

Eye, 2022
Ashish Sharma, Nikulaa Parachuri, Nilesh Kumar, Francesco Bandello, Baruch D. Kuppermann   +4 more
openaire   +3 more sources

Anti-VEGF

2012
openaire   +1 more source

Anti-VEGF Injections and Glaucoma Surgery

JAMA Ophthalmology, 2017
Rajendra S, Apte, Mae, Gordon, Michael A, Kass   +2 more
openaire   +2 more sources